{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:40:28Z","timestamp":1792291228021,"version":"4.4.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.trecan.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T08:10:21Z","timestamp":1580890221000},"page":"98-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":205,"title":["TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines"],"prefix":"10.1016","volume":"6","author":[{"given":"Ashkan","family":"Shahbandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2020.01.007_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"TCGA-Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2020.01.007_bb0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2020.01.007_bb0015","series-title":"The p53 Protein: From Cell Regulation to Cancer","first-page":"173","article-title":"The p53 protein: from cell regulation to cancer","author":"Tonnessen-Murray","year":"2016"},{"key":"10.1016\/j.trecan.2020.01.007_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-386469-7.00005-0","article-title":"TP53 mutations in human cancer: database reassessment and prospects for the next decade","volume":"110","author":"Soussi","year":"2011","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumours to evaluate clinical outcome","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0030","first-page":"2155","article-title":"Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer","volume":"60","author":"Berns","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000123851","article-title":"TP53 status and response to chemotherapy in breast cancer","volume":"75","author":"Bertheau","year":"2008","journal-title":"Pathobiology"},{"key":"10.1016\/j.trecan.2020.01.007_bb0040","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1158\/1078-0432.CCR-13-2943","article-title":"TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance","volume":"20","author":"Silwal-Pandit","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0045","article-title":"Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2020.01.007_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","article-title":"Overview of resistance to systemic therapy in patients with breast cancer","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.trecan.2020.01.007_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1054\/drup.2001.0213","article-title":"If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells","volume":"4","author":"Roninson","year":"2001","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0065","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2008.21.4791","article-title":"Role of anthracyclines in the treatment of early breast cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.radonc.2013.06.013","article-title":"Ionizing-radiation induced DNA double-strand breaks: a direct and indirect lighting up","volume":"108","author":"Vignard","year":"2013","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-199801000-00001","article-title":"Preclinical pharmacokinetics of paclitaxel and docetaxel","volume":"9","author":"Sparreboom","year":"1998","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.trecan.2020.01.007_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc992","article-title":"The role of p53 in determining sensitivity to radiotherapy","volume":"3","author":"Gudkov","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0095","first-page":"246","article-title":"The role of p53 in the response to mitotic spindle damage","volume":"48","author":"Meek","year":"2000","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.trecan.2020.01.007_bb0100","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/cncr.11603","article-title":"Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks","volume":"98","author":"Buchholz","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1359-6349(08)71964-5","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1","volume":"6","author":"Eisenhauer","year":"2008","journal-title":"EJC Suppl."},{"key":"10.1016\/j.trecan.2020.01.007_bb0110","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2000.18.17.3172","article-title":"Selective estrogen receptor modulators: structure, function, and clinical use","volume":"18","author":"Osborne","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsbmb.2005.04.021","article-title":"Aromatase inhibitors: future directions","volume":"95","author":"Osborne","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fonc.2018.00144","article-title":"Precision medicine in hormone receptor-positive breast cancer","volume":"8","author":"Nasrazadani","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0125","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1742-1241.2007.01587.x","article-title":"The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer","volume":"61","author":"Fabian","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.trecan.2020.01.007_bb0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamaoncol.2018.6196","article-title":"Association between reimbursement incentives and physician practice in oncology: a systematic review","volume":"5","author":"Mitchell","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10754-012-9117-y","article-title":"Physician response to financial incentives when choosing drugs to treat breast cancer","volume":"12","author":"Epstein","year":"2012","journal-title":"Int. J. Health Care Finance Econ."},{"key":"10.1016\/j.trecan.2020.01.007_bb0140","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1475-6773.00133","article-title":"Medicare breast surgery fees and treatment received by older women with localized breast cancer","volume":"38","author":"Hadley","year":"2003","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0145","doi-asserted-by":"crossref","first-page":"64910","DOI":"10.18632\/oncotarget.11912","article-title":"Immunohistochemical correlates of TP53 somatic mutations in cancer","volume":"7","author":"Murnyak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.01.007_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/bjc.1996.333","article-title":"Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1\/Cip1 in colorectal carcinoma","volume":"74","author":"Slebos","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-018-0074-x","article-title":"Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity","volume":"3","author":"Shahbandi","year":"2019","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0160","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.humpath.2007.03.005","article-title":"High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas","volume":"38","author":"Valentin-Vega","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/(SICI)1097-0215(19980821)79:4<376::AID-IJC12>3.0.CO;2-3","article-title":"Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors","volume":"79","author":"Norberg","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0170","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1073\/pnas.92.9.3963","article-title":"A simple p53 functional assay for screening cell lines, blood, and tumors","volume":"92","author":"Flaman","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2020.01.007_bb0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026179","article-title":"Somatic TP53 mutations in the era of genome sequencing","volume":"6","author":"Hainaut","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.trecan.2020.01.007_bb0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0027-5107(99)00162-1","article-title":"New approaches to understanding p53 gene tumor mutation spectra","volume":"431","author":"Hollstein","year":"1999","journal-title":"Mutat. Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0185","first-page":"681","article-title":"p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers","volume":"10","author":"Hartmann","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2020.01.007_bb0190","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001016","article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","volume":"2","author":"Robles","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/path.1711640113","article-title":"p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study","volume":"164","author":"Ostrowski","year":"1991","journal-title":"J. Pathol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0200","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1349-7006.1991.tb02710.x","article-title":"Nuclear p53 immunoreaction associated with poor prognosis of breast cancer","volume":"82","author":"Iwaya","year":"1991","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1536","article-title":"p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer","volume":"8","author":"Yamashita","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0210","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1095-1029","article-title":"Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy","volume":"1","author":"Bergh","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2020.01.007_bb0215","first-page":"1485","article-title":"Racial disparity in the association of p53 gene alterations with breast cancer survival","volume":"55","author":"Shiao","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1097-0215(20000120)89:1<32::AID-IJC6>3.0.CO;2-G","article-title":"A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome","volume":"89","author":"Blaszyk","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0225","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdi150","article-title":"Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF","volume":"16","author":"Andersson","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0230","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1111\/j.1582-4934.2008.00553.x","article-title":"Mutations in p53, p53 protein overexpression and breast cancer survival","volume":"13","author":"Rossner","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.trecan.2020.01.007_bb0235","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","volume":"12","author":"Olivier","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0240","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00245","article-title":"Survival outcomes by TP53 mutation status in metastatic breast cancer","author":"Meric-Bernstam","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0245","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-018-1044-5","article-title":"Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment","volume":"20","author":"Ungerleider","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0250","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2020.01.007_bb0255","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1038\/ncomms11479","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2020.01.007_bb0260","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/bjc.1995.497","article-title":"Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy","volume":"72","author":"Archer","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0265","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1997.15.5.1916","article-title":"bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study","volume":"15","author":"Elledge","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0270","doi-asserted-by":"crossref","first-page":"15081","DOI":"10.1073\/pnas.1009575107","article-title":"Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation","volume":"107","author":"Konduri","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2020.01.007_bb0275","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/362847a0","article-title":"p53 is required for radiation-induced apoptosis in mouse thymocytes","volume":"362","author":"Lowe","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2020.01.007_bb0280","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0092-8674(93)90719-7","article-title":"p53-dependent apoptosis modulates the cytotoxicity of anticancer agents","volume":"74","author":"Lowe","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2020.01.007_bb0285","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.onc.1204156","article-title":"p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling","volume":"20","author":"Sablina","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2020.01.007_bb0290","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.2144364","article-title":"Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene","volume":"249","author":"Raycroft","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.trecan.2020.01.007_bb0295","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell's response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0300","first-page":"1391","article-title":"Apoptosis, p53, and tumor cell sensitivity to anticancer agents","volume":"59","author":"Brown","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0305","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1006\/excr.1994.1063","article-title":"Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen","volume":"211","author":"Noda","year":"1994","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0310","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/366704a0","article-title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4","volume":"366","author":"Serrano","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2020.01.007_bb0315","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","article-title":"WAF1, a potential mediator of p53 tumor suppression","volume":"75","author":"el-Deiry","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2020.01.007_bb0320","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1038\/sj.onc.1203078","article-title":"Role of p53 and p21waf1\/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs","volume":"18","author":"Chang","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2020.01.007_bb0325","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(02)09969-5","article-title":"Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy","volume":"360","author":"Bertheau","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2020.01.007_bb0330","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1634\/theoncologist.2009-0243","article-title":"Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers","volume":"15","author":"Lehmann-Che","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.trecan.2020.01.007_bb0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4048\/jbc.2015.18.1.16","article-title":"Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer","volume":"18","author":"Kim","year":"2015","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ijc.29715","article-title":"TP53 mutations are associated with higher rates of pathologic complete response to anthracycline\/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer","volume":"138","author":"Wang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0345","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10549-011-1412-7","article-title":"TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +\/- trastuzumab","volume":"132","author":"Gluck","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0350","first-page":"2505","article-title":"Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer","volume":"61","author":"Geisler","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0355","first-page":"5582","article-title":"TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer","volume":"9","author":"Geisler","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0360","first-page":"50","article-title":"TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients","volume":"6","author":"Kandioler-Eckersberger","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0365","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/annonc\/mdn039","article-title":"p53 status and efficacy of primary anthracyclines\/alkylating agent-based regimen according to breast cancer molecular classes","volume":"19","author":"Bidard","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0370","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/bjc.1998.377","article-title":"Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer","volume":"77","author":"Jarvinen","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0375","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm0796-811","article-title":"Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients","volume":"2","author":"Aas","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2020.01.007_bb0380","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3109\/0284186X.2014.922215","article-title":"TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy","volume":"53","author":"Eikesdal","year":"2014","journal-title":"Acta Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0385","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3179","article-title":"Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline\/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial","volume":"14","author":"Fernandez-Cuesta","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0390","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO;2-Y","article-title":"No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer","volume":"79","author":"Rozan","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0395","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/bjc.1997.484","article-title":"Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer","volume":"76","author":"Niskanen","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019249","article-title":"Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel","volume":"6","author":"Chrisanthar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2020.01.007_bb0405","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","article-title":"Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"132","author":"Esserman","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0410","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/JCO.1998.16.2.470","article-title":"p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer","volume":"16","author":"Clahsen","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0415","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/srep02246","article-title":"The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis","volume":"3","author":"Yang","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2020.01.007_bb0420","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/annonc\/mdl147","article-title":"Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy","volume":"17","author":"Malamou-Mitsi","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0425","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jjco\/hyp007","article-title":"p53 as a specific prognostic factor in triple-negative breast cancer","volume":"39","author":"Chae","year":"2009","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0430","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/jnci\/90.18.1346","article-title":"erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer","volume":"90","author":"Thor","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2020.01.007_bb0435","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0959-8049(02)00499-9","article-title":"A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients","volume":"39","author":"Rahko","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0440","doi-asserted-by":"crossref","first-page":"27997","DOI":"10.18632\/oncotarget.15881","article-title":"Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.01.007_bb0445","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10549-009-0560-5","article-title":"Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy","volume":"121","author":"Kim","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0450","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4143\/crt.2015.430","article-title":"Association between mutation and expression of TP53 as a potential prognostic marker of triple-negative breast cancer","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0455","doi-asserted-by":"crossref","first-page":"67686","DOI":"10.18632\/oncotarget.11891","article-title":"Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline\/taxane-based chemotherapy","volume":"7","author":"Darb-Esfahani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2020.01.007_bb0460","doi-asserted-by":"crossref","first-page":"18060","DOI":"10.1073\/pnas.1018858109","article-title":"Estrogen receptor prevents p53-dependent apoptosis in breast cancer","volume":"44","author":"Bailey","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2020.01.007_bb0465","doi-asserted-by":"crossref","first-page":"9837","DOI":"10.1074\/jbc.C600001200","article-title":"Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function","volume":"281","author":"Liu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2020.01.007_bb0470","doi-asserted-by":"crossref","first-page":"30117","DOI":"10.1074\/jbc.M112.367326","article-title":"p53, a target of estrogen receptor (ER) alpha, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells","volume":"287","author":"Berger","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2020.01.007_bb0475","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-010-0819-x","article-title":"Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines","volume":"125","author":"Fernandez-Cuesta","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.trecan.2020.01.007_bb0480","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/ijc.25512","article-title":"p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines","volume":"128","author":"Fernandez-Cuesta","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0485","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","article-title":"p53-Mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer","volume":"21","author":"Jackson","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2020.01.007_bb0490","first-page":"1876","article-title":"DNA damage is able to induce senescence in tumor cells in vitro and in vivo","volume":"62","author":"te Poele","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2020.01.007_bb0495","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.tranon.2018.05.003","article-title":"p53 Mediates vast gene expression changes that contribute to poor chemotherapeutic response in a mouse model of breast cancer","volume":"11","author":"Tonnessen-Murray","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.trecan.2020.01.007_bb0500","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI64098","article-title":"Cellular senescence and the senescent secretory phenotype: therapeutic opportunities","volume":"123","author":"Tchkonia","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2020.01.007_bb0505","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.trecan.2016.10.001","article-title":"SASP: tumor suppressor or promoter? Yes!","volume":"2","author":"Rao","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.trecan.2020.01.007_bb0510","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1083\/jcb.201904051","article-title":"Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival","volume":"218","author":"Tonnessen-Murray","year":"2019","journal-title":"J. Cell Biol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803320300200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803320300200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:50Z","timestamp":1762505450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803320300200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2405803320300200"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2020.01.007","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}